Prevalence of Oral Mucosal Alterations In a Sample of Egyptian Patients With Cardiovascular Diseases: A Hospital- Based Cross-Sectional Study

NCT04511403 | Unknown

• 1 other identifier: Mucosal changes
• Study Type: observational
• Target: 338
• Locations: 0 countries
• Sites: N/A

Brief Summary

to assess the oral mucosal alterations and their prevalence secondary to use cardiovascular drugs in a sample of Egyptian population with cardiovascular diseases .

Conditions

Cardiac Disease

Outcome Measures

Primary Outcomes (1)

• Oral mucosal manifestations as listed (Dr. Shantala Arunkumar, 2013)

  Clinical examination according to WHO (World Health Organization, 2010) Oral mucosal manifestations as listed (Dr. Shantala Arunkumar, 2013) Clinical examination according to WHO (World Health Organization, 2010) Dichotomous outcome (Yes/No).

  through study completion, an average of 1 year

Secondary Outcomes (2)

• Periodontal condition.(Miranda et al., 2012)

  through study completion, an average of 1 year

• Salivary glands function

  through study completion, an average of 1 year

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hospital- Based Cross-Sectional Study

You may qualify if:

• Patients \>18-years-old. 2-Patients diagnosed with cardiovascular diseases (Ivanuša, 2014). 3-patients taking cardiovascular drugs(Dr. Shantala Arunkumar, 2013).

You may not qualify if:

• Patients not physically able to participate in survey or clinical oral examination.
• Patients under immunosuppressive drugs. 3-Patients with dementia or confusion, severe illness. 4- patients who refuse to participate in the study. 5-patients with hormonal diseases like diabetes mellitus and others. 6-patients with conditions cause xerostomia like Sjogren's syndrome and any medical diseases other than cardiovascular diseases.
• patients suffering from any medical diseases with aphthous ulcer and any other cause of xerostomia than cardiovascular diseases.

Sponsors & Collaborators

• Cairo University: lead

Related Publications (3)

• Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol. 2014 Apr 9;13:76. doi: 10.1186/1475-2840-13-76.

  PMID: 24716628 BACKGROUND

• Jager DHJ, Bots CP, Forouzanfar T, Brand HS. Clinical oral dryness score: evaluation of a new screening method for oral dryness. Odontology. 2018 Oct;106(4):439-444. doi: 10.1007/s10266-018-0339-4. Epub 2018 Jan 22.

  PMID: 29356914 BACKGROUND

• Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis. 2010 Nov;16(8):769-73. doi: 10.1111/j.1601-0825.2010.01686.x.

  PMID: 20604876 BACKGROUND

MeSH Terms

Conditions

Heart Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Central Study Contacts

Mohamed Mostafa Sleem, doctor

CONTACT

01067083315; mohammed.sleem@dentistry.cu.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle investigator

Study Record Dates

• First Submitted: August 8, 2020
• First Posted: August 13, 2020
• Study Start: September 1, 2020
• Primary Completion: September 1, 2022
• Study Completion: October 1, 2022
• Last Updated: August 13, 2020

Record last verified: 2020-08